A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of neoadjuvant carboplatin and mirvetuximab soravtansine in participants with folate receptor alpha (FRα) -expressing advanced-stage serous epithelial ovarian, fallopian tube or primary peritoneal cancer (EOC).
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). This is a single arm study in adult participants with advanced-stage Fédération Internationale de Gynécologie et d'Obstétrique (FIGO) III-IV FRα-expressing serous EOC. Around 140 participants will be enrolled in the study at approximately 80 sites in the United States.
Participants will receive intravenous infusion of MIRV in combination with carboplatin on day 1 of each cycle, every 21 days for up to 6 - 9 Cycles. The total study duration will be approximately 3 years .
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

开始日期2025-11-21

申办/合作机构

AbbVie, Inc.

NCT07059845

/ Recruiting临床2期

A Phase 2, Open-Label, Randomized, Master Protocol Dose Optimization Study to Evaluate Safety and Efficacy of Multiple Treatment Combinations With Mirvetuximab Soravtansine in Subjects With Ovarian Cancer

Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in participants with ovarian cancer (OC). Participants must have confirmation of folate receptor alpha (FRa) positivity by the Ventana folate receptor 1 (FOLR1) Assay.
Mirvetuximab Soravtansine (MIRV) is an investigational drug for the treatment of OC. Participants will be assigned to 1 of 2 substudies and further into groups called treatment arms. In substudy 1, arms A-C, participants will receive 1 of 2 doses of MIRV with Bev, or Bev alone. In substudy 2, arms D and E, participants will receive 1 of 2 doses of MIRV with carboplatin, followed by MIRV alone. Approximately 320 participants will be enrolled in the study at 100 sites around the world.
Participants will receive intravenously (IV) infused MIRV with IV infused carboplatin, or IV infused Bev, or IV infused Bev alone. The total study duration will be approximately 40 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

开始日期2025-11-13

申办/合作机构

AbbVie, Inc.

NCT06682988

/ Recruiting临床2期

A Randomized Phase 2, Open-label Study of Mirvetuximab Soravtansine in Patients With Platinum-resistant Advanced High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-alpha Expression Testing 2 Schedules of Administration for Dose Optimization, With a Separate Cohort to Determine Starting Dose in Patients With Moderate Hepatic Impairment

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy of for Mirvetuximab Soravtansine in participants with platinum-resistant advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancer (platinum-resistant ovarian cancer) (PROC) whose tumors express a high level of folate receptor alpha (FRα).
Mirvetuximab Soravtansine (MIRV) is an investigational antibody drug conjugate designed to selectively kill cancer cells. The antibody (protein) part of MIRV targets tumors by delivering a cell-killing drug to cancer cells carrying a protein called folate receptor alpha (FRα). There are 2 cohorts in this study, the Randomized Phase 2 Cohort and the Hepatic Impairment Cohort. In the Randomized Phase 2 Cohort, participants are placed in 1 of 2 groups, called treatment arms. Each treatment arm receives MIRV on a different schedule (on day 1 every 21 days or on days 1 and 15 every 28 days). The Hepatic Impairment Cohort is designed to determine the starting dose of MIRV in patients with moderately abnormal liver function. Around 110 participants will be enrolled in the study at approximately 75 sites worldwide.
The total study duration will be approximately 24 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.

开始日期2025-05-28

申办/合作机构

AbbVie, Inc.

100 项与索米妥昔单抗相关的临床结果

登录后查看更多信息

100 项与索米妥昔单抗相关的转化医学

登录后查看更多信息

100 项与索米妥昔单抗相关的专利（医药）

登录后查看更多信息

134

项与索米妥昔单抗相关的文献（医药）

2026-03-01·DIAGNOSTIC CYTOPATHOLOGY

Detecting FR ‐⍺ Expression Level in Cytology Effusion Specimens From Ovarian Cancer and Comparing It With Tissue Specimens

Article

作者: Siqian Huang ; Sishi Bai ; Xiaofei Yu ; Yadan Ma ; Baizhou Li ; Xiaohong Duan

ABSTRACT:

Background:

Folate receptor‐⍺ (FR‐⍺) is an attractive target for targeted therapy. Mirvetuximab soravtansine (MIRV) has been approved by the United States Food and Drug Administration (FDA) for treating adult patients with FR‐⍺ positive, platinum‐resistant epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. Therefore, identifying and detecting FR‐⍺ has become an essential part of precision medicine. This study aimed to evaluate the feasibility of detecting FR‐⍺ protein expression in serous cavity effusions using cell blocks (CBs) and compare the results with surgical pathology biopsy or resection specimens. Furthermore, we investigated potential variations in FR‐⍺ expression pre‐ and post‐chemotherapy.

Methods:

Immunohistochemical (IHC) staining of FR‐⍺ was performed on the serous cavity effusion specimens from 35 patients with epithelial ovarian cancer, along with matched surgical pathological (SP) biopsy or resection specimens, following the manufacturer's guidelines for IHC analysis.

Results:

Positive staining was observed in 30 (85.7%) and 32 (91.4%) serous cavity effusion CB and tissue samples, respectively. A total of 31 (88.5%) tissue and 28 (80%) effusion CB samples exhibited moderate‐to‐strong FR‐⍺ expression in at least 25% of tumor cells. A cutoff of 25% for FR‐⍺ expression positivity was used to demonstrate high concordance (96.4%) between cytology CBs and tissue specimens. We recommend a cutoff of 75% viable tumor cells with moderate‐to‐strong membrane staining as “positive” in CBs for greater reliability, which aligns with FDA‐approved criteria. A reasonable consistency was observed in FR‐⍺ expression between the pre‐treatment serous cavity effusion CB specimens and the new biopsy specimens obtained after multiline treatment.

Conclusion:

We demonstrated that serous effusion CB specimens may be effective for FR‐⍺ biomarker detection; FR‐⍺ maintains stable expression pre‐ and post‐chemotherapy, and patients can benefit from MIRV.

2026-02-24·CURRENT TOPICS IN MEDICINAL CHEMISTRY

An Expedition of FDA-Approved Anticancer Drugs in 2024: Synthetic Routes, Mechanisms of Action, and Clinical Indications.

Article

作者: Kurmi, Balak Das ; Priya, Sakshi ; Soni, Reena ; Cherian, Issac V ; Kasana, Shivani ; Islam, Md Mustahidul ; Das, Km Supriya ; Patel, Preeti

The year 2024 witnessed significant advancements in cancer therapy, with the U.S. Food and Drug Administration (FDA) approving 56 anticancer drugs for various malignancies. These approvals encompass 36 organic small molecules and 20 macromolecular monoclonal antibody conjugates, each with distinct mechanisms of action targeting key oncogenic pathways. Among the small molecules, kinase inhibitors such as Ribociclib, Imatinib Mesylate, and Nilotinib Hydrochloride Dihydrate modulate critical signaling cascades, while antimetabolites like Fluorouracil and Pemetrexed Disodium disrupt nucleotide biosynthesis. Other classes include DNA-damaging agents (Mitomycin, Gemcitabine Hydrochloride), immune modulators (Pomalidomide, Lenalidomide), and hormonal antagonists (Abiraterone Acetate, Erleada). The macromolecular therapeutics primarily consist of monoclonal antibody-based agents, such as Keytruda, Tecentriq, and Imfinzi, which enhance immune checkpoint inhibition, and antibody-drug conjugates like Enhertu and Elahere, which deliver cytotoxic payloads with high specificity. This review systematically examines the chemical synthesis, mechanisms of action, and therapeutic indications of these FDAapproved agents, emphasizing their role in improving patient outcomes. By analyzing their structural frameworks and biological targets, we aim to provide insights into current trends in anticancer drug development and potential future directions.

2026-02-01·INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER

Gynecologic cancers in 2025: a year in review

Review

作者: Arenhardt, Martina Parenza ; Nogueira-Rodrigues, Angélica ; Tavares Filgueiras, Ana Beatriz ; Alves, Cassio Bona

Gynecologic cancers remain a leading cause of morbidity and mortality in women, and recent years have marked an inflection point through the consolidation of immunotherapy, the maturation of antibody-drug conjugates, and broader biomarker implementation. This narrative review synthesizes key clinical and translational advances across ovarian, endometrial, and cervical cancers in 2025, emphasizing implications for treatment selection and sequencing. In advanced ovarian cancer, TRUST re-examined surgical timing, supporting primary cytoreduction in selected resectable patients, whereas ICON8B suggested that weekly paclitaxel with carboplatin and bevacizumab may improve outcomes in high-risk disease. Platinum-resistant ovarian cancer saw the most disruptive progress: mirvetuximab soravtansine validated folate receptor-α as a therapeutic target, with overall survival benefit in high-expressing tumors; trastuzumab deruxtecan expanded actionable HER2 disease, with greatest activity in tumors rated 3+ by immunohistochemistry; and combination strategies, including relacorilant plus nab-paclitaxel and pembrolizumab plus weekly paclitaxel ± bevacizumab, delivered clinically meaningful survival signals, underscoring the need for harmonized biomarker strategies and proactive toxicity mitigation. In endometrial cancer, the Cancer Genome Atlas-based molecular classification increasingly informs risk stratification and adjuvant tailoring; long-term PORTEC-3 data refine escalation for p53-abnormal disease and de-escalation considerations for POLE-mutant tumors. In advanced disease, first-line chemo-immunotherapy has matured, with overall survival updates in mismatch repair-deficient tumors and a consistent progression-free survival benefit across diverse mismatch repair-proficient sub-groups, whereas adjuvant immunotherapy remains in evolution after KEYNOTE-B21. In cervical cancer, pembrolizumab added to definitive chemoradiotherapy set a new benchmark in locally advanced disease, and ultra-sensitive circulating tumor DNA analyses emerged as a powerful prognostic tool to enable post-treatment risk-adapted strategies. Collectively, the 2025 data set reinforces a "right therapy, right patient, right time" paradigm and prioritizes confirmatory antibody-drug conjugate trials, resistance biology, and dynamic biomarkers to translate gains into durable, equitable benefit.

833

项与索米妥昔单抗相关的新闻（医药）

2026-04-02

·今日头条

华东医药：创新药领航，医美蓄势待发，风险与机遇并存

华东医药（000963）2025年三季报深度剖析：创新驱动下的稳健增长与潜在风险一、基本面分析：业绩稳健增长，结构持续优化华东医药（000963）2025年前三季度业绩表现稳健，实现营业收入326.64亿元，同比增长3.77%；归母净利润27.48亿元，同比增长7.24%。单三季度来看，公司实现营业收入109.89亿元，同比增长4.53%；归母净利润9.33亿元，同比增长7.71%。利润增速高于收入增速，显示出公司盈利能力的持续改善。从业务板块来看，医药工业板块成为公司业绩增长的核心驱动力。该板块（含CSO业务）前三季度实现营业收入110.45亿元，同比增长11.10%；核心子公司中美华东实现净利润24.75亿元，同比增长15.62%。创新产品销售及代理服务收入达16.75亿元，同比大幅增长62%，成为医药工业板块增长的主要贡献力量。其中，赛恺泽（CAR-T）前三季度有效订单170份，超去年全年；爱拉赫（索米妥昔单抗）依托“港澳药械通”政策率先打开市场，前三季度实现销售收入超4500万元；赛乐信（乌司奴单抗）、惠优静（脯氨酸加格列净）销量逐季快速增长；派舒宁（PARP抑制剂）Q3销量环比倍增。医药商业板块为公司提供了稳定的现金流支撑，前三季度实现营业收入212.53亿元，同比增长3.31%；实现净利润3.34亿元，同比增长3.37%。医美板块则因市场需求恢复不足及市场竞争加剧，前三季度实现营业收入15.68亿元，同比下降17.90%。不过，随着核心产品管线注册进度的推进及新产品在国内的逐步上市，公司医美业务的品牌效应及核心竞争力有望进一步提升。在盈利能力方面，公司毛利率为33.52%，同比上升0.97个百分点；净利率为8.39%，同比上升0.25个百分点。这主要得益于高毛利的创新药收入占比提高及运营效率的优化。期间费用方面，销售费用同比增长1.36%；管理费用同比减少7.55%；研发费用同比大幅增长58.92%；财务费用同比减少70.20%。研发费用的大幅增长彰显了公司对创新研发的重视程度，也为公司的长期发展奠定了坚实基础。二、题材概念分析：创新药与医美双轮驱动，布局前沿领域 1. 创新药概念：研发管线丰富，成果逐步兑现华东医药在创新药领域的布局全面且深入，尤其在GLP-1赛道具有显著优势。公司自主研发的口服小分子GLP-1受体激动剂HDM1002已完成体重管理III期临床入组，用于糖尿病的两项Ⅲ期临床研究也均于2025年8月完成首例受试者入组。GLP-1R/GIPR双靶点长效多肽类激动剂HDM1005注射液已完成体重管理适应症Ⅲ期临床首例受试者入组，糖尿病适应症Ⅱ期临床试验也已完成全部受试者入组。此外，公司在ADC（抗体偶联药物）领域也取得了重要进展。靶向ROR1的ADC项目HDM2005进度位于全球临床研发第一梯队，目前正在国内开展三项临床试验。公司还自主研发了差异化创新靶点ADC药物管线，靶点涵盖FGFR2b、MUC17、CDH17等，均已进入临床阶段。这些创新药管线的推进，不仅丰富了公司的产品矩阵，也为公司的长期增长提供了有力保障。 2. 医美概念：品牌效应提升，核心竞争力增强尽管医美板块前三季度业绩承压，但公司在医美领域的布局并未放缓。公司全资子公司英国Sinclair和国内医美市场子公司欣可丽美学均在积极推进核心产品管线的注册工作，并加快新产品的上市步伐。随着核心产品管线注册进度的推进及新产品在国内的逐步上市，公司医美业务的品牌效应及核心竞争力有望进一步提升。此外，公司还在主动开展组织架构与人员配置的战略性调整，着力构建精练高效、富有创新力的运营体系，为医美业务的后续发展奠定坚实基础。 3. 工业微生物概念：海外拓展稳步推进，增长潜力巨大公司工业微生物板块整体收入继续保持较快增长，前三季度同比增长28.48%。随着海外市场的积极拓展，该板块业务有望延续良好发展趋势。工业微生物业务的增长不仅为公司提供了新的利润增长点，也进一步增强了公司的抗风险能力。三、风险提示：需关注潜在风险，谨慎投资决策 1. 新产品导入不及预期风险尽管公司在创新药和医美领域取得了显著进展，但新产品的导入仍面临诸多不确定性因素。如临床试验结果不及预期、注册审批进度延迟等，都可能影响新产品的上市时间和市场表现，进而对公司业绩产生不利影响。 2. 居民消费信心恢复不足风险医美板块业绩承压的主要原因之一是居民消费信心恢复不足。若未来居民消费信心持续低迷，将对医美市场的需求产生负面影响，进而影响公司医美业务的业绩表现。 3. 产品安全风险医药行业对产品安全性要求极高。若公司产品在生产、销售或使用过程中出现安全问题，将对公司声誉和业绩产生严重负面影响。因此，公司需持续加强产品质量管控和风险防控体系建设。 4. 医药商业业务受宏观环境变动影响的风险医药商业业务受宏观经济环境、政策法规等因素影响较大。若未来宏观经济环境恶化或政策法规发生不利变化，将对公司医药商业业务的业绩产生负面影响。 5. 研发费用大幅增长带来的盈利压力公司研发费用同比大幅增长58.92%，虽然彰显了公司对创新研发的重视程度，但也对公司的盈利能力带来了一定压力。若未来研发费用持续高速增长而创新药销售收入未能及时跟上，将对公司的盈利水平产生不利影响。四、总结与展望华东医药（000963）2025年三季报显示，公司业绩稳健增长，结构持续优化。医药工业板块成为公司业绩增长的核心驱动力，创新药研发管线丰富且成果逐步兑现；医美板块虽面临挑战但品牌效应提升、核心竞争力增强；工业微生物板块增长潜力巨大。然而，公司也面临新产品导入不及预期、居民消费信心恢复不足等潜在风险。未来，公司需继续加强创新研发、优化业务结构、提升运营效率，以应对潜在风险并实现可持续发展。 ★ 点赞关注不迷路，评论区灵感请你补！ ★ 感悟：敬畏市场，保持谦逊。价值投资，保持耐心，或顺势而为，跟趋势，控仓位，设止损。情绪管理，避免贪婪和恐惧，保持平和心态。择势择时择股择价，每日复盘与总结。 ★★★重要提醒★★★ 本文为作者研读日记，数据来源于网络公开资料，不保证准确和完整，不作为任何参考依据，不作推荐，不构成即可操作建议，据此操作，风险自担。

财报免疫疗法细胞疗法临床3期

2026-04-02

·ioncology

2026 SGO年会快速口头报告：四场会议内容精粹

2026年美国妇科肿瘤学会（SGO）年会设置了丰富的学术板块，包括大师班（Masterclass）、科学全体会议（Scientific Plenary）、专题论坛（Focused Forum）、行业卫星会（ISS）、快速口头报告（Rapid-Fire Oral）、壁报导览（Poster Tour）和互动工作坊（Workshop）等类型。快速口头报告环节以简短高效的形式，呈现遗传学、手术、转化医学、健康差异等领域的最新研究数据。本文介绍四场快速口头报告的内容。快速口头报告I: 遗传学、预防与手术（Genetics, Prevention and Surgery）时间：2026年4月11日（星期六）3:00 - 4:00 PM 地点：104号厅主持人：Kaitlin Dwyer, PA-C (MD安德森癌症中心), Melissa Frey, MD, MS (威尔康奈尔医学院) 胰高血糖素样肽-1受体激动剂与非糖尿病肥胖女性的肥胖相关癌症累积发病率降低相关 Glucagon-Like Peptide-1 Receptor Agonists Are Associated With a Reduced Cumulative Incidence of Obesity-Associated Cancers in Obese Non-Diabetic Women 讲者: Heng-Cheng Hsu, MD (休斯顿卫理公会医院) 基于实验室研究注册库，子宫内膜癌患者（诊断年龄在65岁以下和以上）的生殖系致病性变异发生率 Prevalence of germline pathogenic variants in patients with endometrial cancer diagnosed before and after 65 years old within a laboratory-based research registry 讲者: Kieran Seay, MD/PhD (匹兹堡大学医学中心) 在低人群患病率下，对子宫内膜上皮内瘤变进行错配修复蛋白免疫组化检测诊断林奇综合征具有成本效益 Immunohistochemistry for mismatch repair protein expression in endometrial intraepithelial neoplasia is cost effective to diagnose Lynch Syndrome at low population prevalence 讲者: Hadley Reid (布莱根妇女医院 / 麻省总医院) 针对BRCA1/2致病性变异携带者的群体教育干预随机可行性研究 A randomized feasibility study of group-based education intervention for BRCA1/2 pathogenic variant carriers 讲者: Isabel Beshar, MD, MPhil (MD安德森癌症中心) 宫颈拭子中TUBB6甲基化用于卵巢癌检测：初步性能 TUBB6 Methylation in Cervical Swabs for Ovarian Cancer Detection: Primarily Performance 讲者: Kuo-Min Su, MD, PhD (三军总医院，国防医学院) 多癌种早期检测在降低宫颈癌、卵巢癌和子宫内膜癌死亡率中的潜力 The Potential of Multi-Cancer Early Detection Tests for Reducing Cancer Mortality in Cervical, Ovarian, and Endometrial Cancers 讲者: Elle Grevstad, PhD (Exact Sciences) 要点总结讲者: Lee-may Chen, MD (加州大学旧金山分校海伦·迪勒家庭综合癌症中心) 问答环节术中包膜破裂对I期黏液性卵巢癌的预后影响 Prognostic impact of intraoperative capsule rupture in stage I mucinous ovarian carcinoma 讲者: Christian Dagher, MD MSc (宾夕法尼亚大学医院) I期恶性卵巢生殖细胞肿瘤患者保留生育功能的卵巢囊肿切除术的应用及治疗结局 Utilization and outcomes of fertility-sparing ovarian cystectomy for stage I malignant ovarian germ cell tumors 讲者: Delanie Ludmir, MD Candidate (哥伦比亚大学瓦格洛斯内外科医学院) 鞘内注射吗啡联合术中利多卡因输注vs硬膜外麻醉联合术后PCA用于剖腹探查术患者：一项随机对照试验 Comparing Intrathecal Morphine with Intraoperative Lidocaine Infusion to Epidural Anesthesia with Postoperative PCA for Patients Undergoing Exploratory Laparotomy: A Randomized Controlled Trial 讲者: Alexander Cohen, MD (拉什大学医学中心) 要点总结讲者: Katherine Kurnit, MD, MPH (芝加哥大学) 问答环节快速口头报告II：医疗差异与医疗可及性、患者考量（Disparities and Access to Care, Patient Considerations）时间：2026年4月11日（星期六）4:30 - 5:30 PM 地点：104号厅主持人：Brooke Sanders, MD (圣路易斯华盛顿大学) 波多黎各宫颈腺癌患者的HPV基因分型：对疫苗覆盖和监测的启示 HPV Genotyping in adenocarcinoma of the cervix in patients living in Puerto Rico: Implications for Vaccine Coverage and Surveillance 讲者: Ana Rosario Santos, MD, MPH (迈阿密大学西尔维斯特综合癌症中心) 打破生存差距：临床试验作为妇科癌症结局的平衡器 Breaking the Survival Gap: Clinical Trials as Equalizers in Gynecologic Cancer Outcomes 讲者: Rachael Piver, MD (佐治亚医学院) 实体器官移植后宫颈癌筛查率低的相关因素 Factors associated with low uptake of cervical cancer screening post-solid organ transplant 讲者: Katherine Cooke, MD (明尼苏达大学) 改善医疗可及性：医生和高级执业医师在宫颈癌前病变诊断中的表现 Improving Access to Care: Physician and Advanced Practice Provider Performance in Cervical Preinvasive Disease Diagnosis 讲者: Alexandra North, MD (阿拉巴马大学伯明翰分校) 手术之痛：妇科肿瘤医生工作相关疼痛与损伤 Surgery Hurts: The Burden of Work-Related Pain and Injuries Among Gynecologic Oncologists 讲者: Elizabeth Adams, MD (斯坦福大学) 要点总结讲者: Jennifer Young Pierce, MD, MPH (南阿拉巴马大学米切尔癌症研究所) 问答环节强制完成生命末期表格可降低妇科肿瘤患者的住院死亡率 Mandatory Completion of End-of-Life Forms (eMOLSTs) Reduces Inpatient Mortality in Gynecologic Oncology Patients 讲者: Antalya Jano, MD (纽约大学格罗斯曼医学院) 支持高风险I-II期子宫内膜样子宫内膜癌辅助治疗升级的因素：一项倾向性评分加权研究 Factors Supporting Adjuvant Treatment Escalation in High-Risk Stage I-II Endometrioid Endometrial Carcinoma: A Propensity Score Weighed Investigation 讲者: Samantha Leite, MD (国家首都联盟) 一项倾向性评分加权分析发现：在低级别I期子宫内膜样卵巢癌、输卵管癌和腹膜癌患者中，辅助化疗对比观察有相似生存结局 Similar Survival Outcomes Following Adjuvant Chemotherapy Versus Observation in Low-Grade, Stage I Endometrioid Ovarian, Tubal and Peritoneal Carcinoma: A Propensity Score Weighted Analysis 讲者: Samantha Leite, MD (国家首都联盟) 基于分子分型预测子宫内膜癌患者接受“保留生育功能孕激素治疗”的疗效 Prediction of Response to Fertility Preserving Progestin Therapy for Endometrial Cancer Based on Molecular Subtype 讲者: Oleksandra Dzyubak, MD (多伦多大学) 要点总结讲者: Alexander Melamed, MD MPH (麻省总医院 / 哈佛医学院) 问答环节快速口头报告III：转化医学与抗体药物偶联物（Translational and ADC）时间：2026年4月12日（星期日）12:00 - 1:00 PM 地点：104号厅主持人：Sarah Ferguson, MD (玛格丽特公主医院), Fiorella Reyes Baez, MD (波多黎各大学医学院) 整合单细胞分析揭示TNFAIP3为乳酰化调控卵巢癌化疗耐药的关键因子 Integrated Single-cell Profiling Identifies TNFAIP3 as a Lactylation-Driven Regulator of Chemoresistance in Ovarian Cancer 讲者: 黄慧霞 (复旦大学附属肿瘤医院) CCNE1扩增对无BRCA突变的新诊断卵巢癌患者无进展生存期和总生存期的影响 Impact of CCNE1 amplification on progression-free and overall survival among patients with newly diagnosed ovarian cancer without a BRCA mutation 讲者: Stephen Graves, MD (纪念斯隆凯特琳癌症中心) 在尼拉帕利和多斯塔利单抗治疗复发性或持续性子宫浆液性癌的II期试验中分析免疫组库特征 Profiling the Immune Repertoire in a Phase II Trial of Niraparib and Dostarlimab in Recurrent or Persistent Uterine Serous Carcinomas 讲者: Caprice Eisele, BS (俄亥俄州立大学) 卡铂联合CHK1抑制剂在临床前小鼠模型中克服高级别浆液性卵巢癌铂耐药 Combination of carboplatin and CHK1 inhibition to overcome platinum resistance in high grade serous ovarian cancer in preclinical mouse models 讲者: Mackenzie Cummings, MD (南阿拉巴马大学米切尔癌症研究所) 要点总结讲者: Tyler Hillman, MD, PhD (加州大学圣地亚哥分校) 问答环节索米妥昔单抗联合卡铂治疗叶酸受体α表达的复发性铂敏感卵巢癌 Mirvetuximab soravtansine plus carboplatin in folate receptor alpha-expressing recurrent platinum-sensitive ovarian cancer 讲者: Gottfried Konecny, MD (加州大学洛杉矶分校医学系) 抗体药物偶联物（ADC）靶点的全面分析揭示了子宫内膜癌的组织学特异性和共表达模式 Comprehensive Profiling of antibody-drug conjugate (ADC) Targets Reveals Histology-Specific and Co-Expression Patterns in Endometrial Carcinoma 讲者: Kosuke Shigematsu, MD (埼玉医科大学国际医疗中心) 新型B7H3 ADC (DB1311/BNT324)单药用于经治晚期宫颈癌或铂耐药复发性卵巢癌患者的全球1/2期研究：按既往治疗分层的结局 A global, phase 1/2 study of DB1311/BNT324 (a novel B7H3 ADC) monotherapy in patients with previously treated advanced cervical cancer or platinum-resistant recurrent ovarian cancer: Outcomes by prior treatment 讲者: Ira Winer, MD, PhD (韦恩州立大学) 高级别浆液性癌中FOLR表达的表观遗传驱动因素 Epigenetic drivers of FOLR expression in high grade serous carcinoma 讲者: Katharine Linder, MD (科罗拉多大学安舒茨医学校区) 要点总结讲者: Debra Richardson, MD (俄克拉荷马大学健康科学中心) 问答环节快速口头报告IV：长期试验结局（Long-term Trial Outcomes）时间：2026年4月13日（星期一）9:30 - 10:30 AM 地点：208号厅主持人：David Cantu De Leon, MD, PHD (国家癌症研究所), Roisin O'Cearbhaill, MD (纪念斯隆凯特琳癌症中心) 来自ENGOT-ov65/KEYNOTE-B96 III期试验（帕博利珠单抗对比安慰剂联合紫杉醇±贝伐珠单抗治疗铂耐药复发卵巢癌）的患者报告结局 Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab versus placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer 讲者: Emese Zsiros, MD, PhD (罗斯威尔公园综合癌症中心) 联合PP2A抑制与PD-1阻断（LB-100和多斯塔利单抗）治疗卵巢透明细胞癌 Combination PP2A inhibition and PD-1 blockade with LB-100 and dostarlimab in ovarian clear cell carcinoma 讲者: Helen Clark, MD (德克萨斯大学MD安德森癌症中心) 妇科肿瘤患者接受帕博利珠单抗治疗的免疫相关不良事件：临床试验证据与现实世界经验 Immune-related adverse effects in gynecologic oncology patients on pembrolizumab: trial evidence vs real-world experience 讲者: Ellery Sarosi, MD (密歇根大学) 来自PRIMA/ENGOT-OV26/GOG-3012试验（尼拉帕利一线维持治疗新诊断晚期卵巢癌）最终分析的患者报告结局：基于同源重组缺陷状态的结果 Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: results from the homologous recombination-deficient subgroup 讲者: Floor Backes, MD (俄亥俄州立大学) 对于复发性颗粒细胞瘤患者，二次肿瘤细胞减灭术后辅助治疗的效果 Effect of adjuvant treatment after secondary cytoreductive surgery in patients with recurrent granulosa cell tumor 讲者: Elio Tahan, MD (MD安德森癌症中心) 要点总结讲者: Premal Thaker, MD (圣路易斯华盛顿大学) 问答环节超越Sedlis标准：验证I期宫颈鳞癌和腺癌的组织学特异性风险因素 Beyond Sedlis: Validation of histology-specific risk factors for stage I cervical squamous cell carcinoma and adenocarcinoma 讲者: Tullia Rushton, MD (厄兰格医院) 1b/2a期随机、双盲研究显示新型抗病毒阴道插入物（药物递送装置）ABI-2280治疗持续性高危/致癌HPV感染的潜力 Phase 1b/2a randomized, double-blind study demonstrates potential of ABI-2280, a novel antiviral vaginal insert for the treatment of persistent high-risk/oncogenic HPV infection 讲者: Warner Huh, MD, FCOG, FACS (阿拉巴马大学伯明翰分校) 局部晚期宫颈癌对大分割放疗的病理反应 Pathologic response to hypofractionation in locally advanced cervical cancer 讲者: David Cantu De Leon, MD, PHD (国家癌症研究所) IVB期宫颈癌中孤立性远处淋巴结转移的预后意义 Prognostic significance of distant lymph node metastases alone in stage IVB cervical cancer 讲者: Christian Dagher, MD MSc (宾夕法尼亚大学医院) 要点总结讲者: Dana Chase, MD (加州大学洛杉矶分校大卫·格芬医学院) 问答环节（来源：《肿瘤瞭望》编辑部）声明凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

临床研究

2026-04-01

·摩熵医药

国内51款新药IND获批！61款品种过评，石家庄四药等4家大丰收

注：本文不构成任何投资意见和建议，以官方/公司公告为准；本文仅作医疗健康相关药物介绍，非治疗方案推荐（若涉及），不代表平台立场。任何文章转载需要得到授权。 PART 01 周报概述随着全球医药行业的快速发展，新药研发与创新已成为推动行业进步的重要动力。近期，根据摩熵医药数据统计，新药申请与审批获批频繁，显示出医药创新领域的活跃态势。本文将深入分析2026年3月23日至2026年3月29日期间，国内外新药申请、临床试验批准、仿制药一致性评价等多个方面的最新进展，为用户提供全面的行业资讯。 PART 02 国内51款新药IND获批根据摩熵医药数据库统计，2026年3月23日至2026年3月29日期间，共有64个创新药/改良型新药临床申请/上市申请获国家药品监督管理局药品审评中心（CDE）承办（按受理号统计，不含补充申请）。其中国产药品受理号62个，进口药品受理号2个。本周共计51款创新药/改良型新药临床试验申请获得“默示许可”，包括化学药21款，生物药28款，2款中药。本周获批临床创新药/改良型新药部分信息速览（不含补充申请）注：完整数据可识别“文末”二维码下载查看 PART 03 本周全球TOP10创新药研发进展 3月24日，CDE官网公示显示，礼来（Eli Lilly and Company）申报的1类新药注射用LY4170156获批临床，拟定适应症为：单药治疗既往接受过含铂药物治疗方案的铂耐药卵巢癌成人患者。公开资料显示，sofetabart mipitecan（LY4170156）是一款新型叶酸受体α（FRα）靶向的抗体偶联药物（ADC），采用专有连接子技术，并以exatecan作为有效载荷。2026年1月，礼来宣布美国FDA授予LY4170156突破性疗法认定，用于治疗既往接受过贝伐珠单抗和ADC疗法mirvetuximab soravtansine（如适用）的铂耐药性上皮性卵巢癌、输卵管癌或原发性腹膜癌成年患者。截图来源：全球药物研发数据库（查数据.找摩熵） 3月26日，金赛药业宣布，其在研新药GenSci128继胰腺癌后，胃癌适应症再获美国FDA授予孤儿药资格。GenSci128片是一种针对TP53Y220C突变的选择性重激活剂，在中国属于治疗用化药1类新药，旨在选择性地与TP53Y220C突变蛋白的口袋结合，从而恢复TP53Y220C突变蛋白的正常构象，增加稳定性，恢复转录和抑制肿瘤的功能。据金赛药业新闻稿介绍，GenSci128片拟用于治疗携带TP53Y220C突变的多种实体瘤，包括胃癌、胰腺癌、卵巢癌、乳腺癌、结直肠癌等。该药物新药临床试验申请已获FDA及中国药监部门批准。截图来源：全球药物研发数据库（查数据.找摩熵）本周全球 TOP10 创新药研发进展截图来源：摩熵医药周报 PART 04 本周全球TOP10积极/失败临床结果本周全球Top 10临床进展盘点：本周全球多项临床试验结果表现亮眼。3月24日，信达生物宣布依莫芙普-α在中国新生血管性年龄相关性黄斑变性（nAMD）人群中开展的III期临床研究（STAR）达成52周主要终点。在此研究中，依莫芙普-α视力改善效果非劣效于阿柏西普，同时展现了16周超长间隔给药的临床优势以及降低MA（黄斑萎缩）发生的潜力。依莫芙普-α（IBI302）是信达生物自主研发的一种靶向重组人血管内皮生长因子受体（VEGFR）和人补体受体1（CR1）的双特异性重组全人源融合蛋白，其N端为VEGF结合域，能够与VEGF家族结合阻断VEGF介导的信号通路，抑制血管内皮细胞的生存、增殖，从而抑制血管新生，降低血管渗透性，减少血管渗漏；其C端为补体结合域，能够通过特异性结合C3b和C4b，抑制补体经典途径和旁路途经的激活，减轻补体活化介导的炎症反应。截图来源：全球药物研发数据库（查数据.找摩熵） 3月24日，远大医药(0512.HK)在放射性核素偶联药物(RDC)领域的战略合作伙伴Telix Pharmaceuticals Limited 用于治疗前列腺癌的全球创新药物TLX591-Tx (177Lu rosopatamab tetraxetan)的国际多中心III期临床试验(ProstACT Global)的第一部分（安全性和剂量学引导）已成功达到主要目标，证明了该产品的安全性和耐受性，且未观察到新的不良反应。本次该试验第一部分的主要研究结果包括：安全性及耐受性：联合治疗组的安全性良好，TLX591-Tx的耐受性与既往研究结果一致，未观察到新的安全性信号。血液学事件：血液学事件均为短暂且可控，其发生率与此类疗法和疾病程度的预期情况相符。剂量学数据：关键器官的辐射暴露远低于既定安全限值，所有队列的肿瘤部位均观察到药物摄取，且药代动力学显示药物活性可持续15天，未见明显药物间相互作用。本周全球 TOP10 积极/失败临床结果截图来源：摩熵医药周报 PART 05 61款品种过评，石家庄四药等4家大丰收根据摩熵医药数据库统计，2026年3月23日至2026年3月29日期间，共有49项仿制药申报上市/申报临床获CDE承办，其中新注册分类上市申请受理号47项（包括化药3类，4类），一致性评价申请2项。本周16个品种通过一致性评价（按受理号计21项），本周45个品种视同通过一致性评价（按受理号计59项）。本周1个生物类似物注册申报动态：上海生物制品研究所有限责任公司的利妥昔单抗注射液。本周过评/视同过评品种主要为心血管系统药物；过评/视同过评产品剂型主要为注射剂。截图来源：摩熵医药周报本周盐酸尼卡地平注射液过评/视同过评受理号最多，为5个，同时该品种过评/视同过评企业最多，为3家；本周江苏神龙药业有限公司、新乡市常乐制药有限责任公司、北京双鹭药业股份有限公司和石家庄四药有限公司过评/视同过评品种最多，均为2个，本周过评/视同过评企业包括江苏神龙药业有限公司、新乡市常乐制药有限责任公司、北京双鹭药业股份有限公司和石家庄四药有限公司共64家。截图来源：摩熵医药周报本周，硫酸妥布霉素注射液、维生素B12注射液、甲磺酸贝舒地尔片、乳酸钠林格冲洗液4款为首次过评/视同过评品种。截图来源：摩熵医药周报本周，伊布替尼胶囊、盐酸拉贝洛尔注射液、溴莫尼定噻吗洛尔滴眼液3个药品品种，通过（或视同通过）一致性评价的企业数量已达7家。截图来源：摩熵医药周报摩熵咨询本期完整周报识别二维码领取下载 END 本文为原创文章，转载请留言获取授权近期热门资源获取中国临床试验趋势与国际多中心临床展望-202505 2024年医药企业综合实力排行榜-202505 中国带状疱疹疫苗行业分析报告-202505 2023H2-2024H1中国药品分析报告-202504 数据透视：中药创新药、经典验方、改良型新药、同名同方的申报、获批、销售情况-202503 点击阅读原文，申请摩熵医药企业版免费试用！

孤儿药临床申请抗体药物偶联物一致性评价突破性疗法

100 项与索米妥昔单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10954	索米妥昔单抗	-	DB12489

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
铂敏感性卵巢上皮癌	加拿大	AbbVie, Inc.	2025-08-01
输卵管癌	英国	AbbVie Ltd.	2025-07-24
卵巢癌	英国	AbbVie Ltd.	2025-07-24
原发性腹膜癌	英国	AbbVie Ltd.	2025-07-24
叶酸受体α 阳性铂类耐药的卵巢上皮癌	美国	ImmunoGen, Inc.	2022-11-14
叶酸受体α阳性铂类耐药的输卵管癌	美国	ImmunoGen, Inc.	2022-11-14
叶酸受体α阳性铂类耐药的原发性腹膜癌	美国	ImmunoGen, Inc.	2022-11-14
铂耐药上皮性卵巢癌	美国	ImmunoGen, Inc.	2022-11-14
铂耐药性输卵管癌	美国	ImmunoGen, Inc.	2022-11-14
铂类耐药性原发性腹膜癌	美国	ImmunoGen, Inc.	2022-11-14

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肿瘤	申请上市	加拿大	AbbVie, Inc.	2025-03-01
铂敏感性输卵管癌	临床3期	美国	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	中国	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	日本	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	阿根廷	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	澳大利亚	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	比利时	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	巴西	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	保加利亚	AbbVie, Inc.	2023-03-15
铂敏感性输卵管癌	临床3期	加拿大	AbbVie, Inc.	2023-03-15

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ESGO2026	N/A	铂耐药性卵巢癌 folate receptor alpha (FRα)-positive	22	Mirvetuximab Soravtansine (MV)	餘襯築醖鑰醖範蓋獵範(窪淵蓋壓膚壓齋製鹹鏇) = 壓願鹽衊醖構糧夢鏇衊醖糧繭鑰繭積膚餘網繭 (鬱鹹壓顧製鏇鹹膚構夢 ) 更多	积极	2026-02-28
NCT05041257 (PICCOLO, CTgov)	临床2期	铂敏感性卵巢上皮癌 \| 铂类耐药性原发性腹膜癌 \| 腹膜癌 ... 更多	79	Mirvetuximab soravtansine	糧餘築襯糧鏇憲範夢膚 = 獵衊築襯窪鹽範選醖簾製鏇鹹鬱簾積製築遞齋 (齋觸鬱壓窪構鑰鑰積積, 鑰齋製築簾鏇淵艱願窪 ~ 鹽繭蓋鏇築觸襯積齋憲) 更多	-	2026-01-09
NCT04209855 (MIRASOL, ESMO2025) 人工标引	临床3期	叶酸受体α 阳性铂类耐药的卵巢上皮癌 Folate receptor alpha Positive	453	Mirvetuximab soravtansine (MIRV)	艱窪衊糧鏇淵遞構醖鏇(製壓遞構簾艱糧廠鬱獵) = 鹹製蓋顧積糧選鑰憲構獵繭憲繭窪網餘糧廠簾 (醖製獵鹹窪遞壓壓鬱壓, 4.3 ~ 5.9) 更多	积极	2025-10-17
NCT04209855 (MIRASOL, ESMO2025) 人工标引	临床3期	叶酸受体α 阳性铂类耐药的卵巢上皮癌 Folate receptor alpha Positive	453	Investigator’s choice chemotherapy (ICC)	艱窪衊糧鏇淵遞構醖鏇(製壓遞構簾艱糧廠鬱獵) = 鏇選選壓觸艱鹽構糧簾獵繭憲繭窪網餘糧廠簾 (醖製獵鹹窪遞壓壓鬱壓, 2.9 ~ 4.5) 更多	积极	2025-10-17
NCT05041257 (PICCOLO, ESMO_TAT Asia2025) 人工标引	临床2期	铂敏感性卵巢癌 FRα-positive	38	Mirvetuximab soravtansine-gynx (MIRV) 6 mg/kg (HRD-positive)	壓範膚襯鬱簾膚蓋蓋淵(鬱願艱蓋鹹製鹹蓋膚膚) = 醖網築餘壓廠廠遞觸構淵壓壓鏇醖網製糧窪鑰 (構廠簾衊齋齋糧淵獵夢 ) 更多	积极	2025-06-01
NCT05041257 (PICCOLO, ESMO_TAT Asia2025) 人工标引	临床2期	铂敏感性卵巢癌 FRα-positive	38	Mirvetuximab soravtansine-gynx (MIRV) 6 mg/kg (HRD-negative)	壓範膚襯鬱簾膚蓋蓋淵(鬱願艱蓋鹹製鹹蓋膚膚) = 膚膚壓醖壓夢壓醖衊鹽淵壓壓鏇醖網製糧窪鑰 (構廠簾衊齋齋糧淵獵夢 ) 更多	积极	2025-06-01
ARVO2025	N/A	女性生殖器官肿瘤	14	Mirvetuximab Soravtansine (MIRV) (gynecologic malignancies)	壓觸淵艱繭選鹹積齋繭(獵鏇糧淵鹽襯膚顧夢襯) = At the most severe presentation, keratopathy and punctate epithelial erosions were present in all eyes, with microcystic changes in 50% (14). Corneal haze (1/28, 3.6%) and subepithelial deposits (3/28, 10.7%) were also noted. Non-visually significant cataracts were present in 64.3% (18) of eyes at baseline. Two eyes developed posterior subcapsular cataracts, and 9 eyes underwent cataract surgery while on MIRV. Anterior uveitis developed in 25% (7) eyes, which included 3 eyes with a prior history of non-granulomatous anterior uveitis. No corneal ulcers or epithelial defects were observed. 鹽壓襯蓋願鹹製簾壓範 (醖壓壓顧鑰願簾構製壓 ) 更多	不佳	2025-05-04
NEWS \| Literature 人工标引	N/A	铂耐药性卵巢癌	18	索米妥昔单抗	構遞襯範壓壓餘獵淵鏇(網淵遞鬱願積獵觸構廠) = 鑰憲獵鬱醖鏇範顧鏇鬱築簾遞願簾齋構遞餘廠 (顧繭窪遞膚選顧鬱齋鹽 ) 更多	积极	2025-03-31
NCT04209855 (MIRASOL, PRNewswire \| NEWS) 人工标引	临床3期	叶酸受体α 阳性铂类耐药的卵巢上皮癌 FRα expression	453	ELAHERE (mirvetuximab soravtansine-gynx)	顧糧範製顧鬱廠鏇糧願(觸鏇齋壓繭鏇遞糧簾蓋) = 鹹顧窪壓繭衊鏇鬱鏇淵鬱觸遞蓋鬱憲製窪構襯 (艱構範繭觸繭繭範獵齋, 4.34 ~ 5.88) 更多	积极	2025-03-15
NCT04209855 (MIRASOL, PRNewswire \| NEWS) 人工标引	临床3期	叶酸受体α 阳性铂类耐药的卵巢上皮癌 FRα expression	453	Chemotherapy	顧糧範製顧鬱廠鏇糧願(觸鏇齋壓繭鏇遞糧簾蓋) = 遞鑰網廠廠願觸範壓憲鬱觸遞蓋鬱憲製窪構襯 (艱構範繭觸繭繭範獵齋, 2.86 ~ 4.47) 更多	积极	2025-03-15
NCT05041257 (PICCOLO, Pubmed \| Ann Oncol \| ESMO_TAT Asia2024 \| NEWS) 人工标引	临床2期	卵巢癌三线 FRα expression	79	Mirvetuximab Soravtansine	鏇夢範夢鹹糧鏇鏇齋築(繭膚觸顧願膚夢壓願齋) = 齋衊獵選構齋齋選願繭遞憲遞壓壓積觸鏇繭膚 (製鏇網衊網簾鬱艱壓顧, 40.4 ~ 63.3) 达到更多	积极	2024-11-01
	临床2期	卵巢癌三线 FRα expression	79	Mirvetuximab Soravtansine (PARPi naïve)	鏇夢範夢鹹糧鏇鏇齋築(繭膚觸顧願膚夢壓願齋) = 夢窪觸餘簾鹽鑰膚鬱選遞憲遞壓壓積觸鏇繭膚 (製鏇網衊網簾鬱艱壓顧, 42.8 ~ 94.5) 达到更多	积极	2024-11-01
SGO2024	N/A	毒性 high folate-receptor alpha expression (FOLR)	-	Mirvetuximab soravtansine	壓遞獵構餘壓糧願膚襯(艱繭襯簾膚構鹽廠選獵) = 9 % experienced grade 3 ocular adverse reactions 選積憲顧鹽鹹遞蓋築簾 (鑰蓋網願窪壓衊膚獵淵 ) 更多	-	2024-11-01
NCT05041257 (PICCOLO, ESMO2024) 人工标引	临床2期	原发性腹膜癌 \| 铂敏感性卵巢癌 \| 输卵管癌三线 FRα expression	79	Mirvetuximab soravtansine (MIRV) 6 mg/kg	廠鏇齋簾範鹽淵構鬱鏇(願範簾鹹鬱網繭餘構醖) = 醖積選膚繭醖糧構壓繭積積觸觸顧衊糧築糧鹽 (範淵選醖繭鹹窪積網衊, 40.4 ~ 63.3) 更多	积极	2024-09-15